Aardvark Therapeutics, Inc.
AARD evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AARD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AARD
Aardvark Therapeutics is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies that activate TAS2R bitter taste receptors for metabolic and inflammatory diseases, with lead candidate ARD-101 in clinical development.
Key risk: No approved products or revenue
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 2 clinical trials for Aardvark Therapeutics, Inc..
Aardvark Therapeutics is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies that activate TAS2R bitter taste receptors for metabolic and inflammatory diseases, with lead candidate ARD-101 in clinical development.
- Lead product candidate ARD-101 targets TAS2R signaling for metabolic indications; ARD-201 program is also in development [sec_mda · as of 2025-11-13].
- As of June 30, 2026, the company had cash, cash equivalents and short-term investments of $73.9 million, expected to fund operations into late 2027 [sec_mda · as of 2026-08-11].
- Accumulated deficit was $151.9 million as of June 30, 2026, with net losses of $36.0 million for the six months ended June 30, 2026 [sec_mda · as of 2026-08-11].
- Completed IPO in February 2025, raising net proceeds of approximately $87.5 million from the sale of 6,120,661 shares at $16.00 per share [sec_mda · as of 2026-05-07].
- Has an at-the-market (ATM) facility for up to $150.0 million in common stock sales, but had not sold any shares under it as of June 30, 2026 [sec_mda · as of 2026-08-11].
What works
- Focus on TAS2R receptor activation is a novel mechanism with potential applicability across metabolic and inflammatory diseases with high unmet need [sec_mda · as of 2025-11-13].
- Cash runway into late 2027 provides a multi-year development horizon without near-term financing pressure [sec_mda · as of 2026-08-11].
- IPO proceeds of ~$87.5 million and an untapped $150M ATM facility offer financial flexibility for clinical advancement [sec_mda · as of 2026-05-07].
What to weigh
- No approved products or revenue; the company has incurred significant net losses since inception and expects losses to continue [sec_mda · as of 2026-08-11].
- Accumulated deficit of $151.9 million as of June 30, 2026, with net losses increasing year-over-year ($36.0M vs $23.7M for six-month periods) [sec_mda · as of 2026-08-11].
- Clinical-stage pipeline is highly dependent on successful development and regulatory approval of ARD-101, with no guarantee of success [sec_mda · as of 2026-08-11].
- Relies on third parties for clinical trials and manufacturing, introducing operational and regulatory risks [sec_mda · as of 2026-08-11].
From the filings
Quoted directly from source documents.
Cash runway into late 2027
“Based upon our current operating plans, we believe that our existing cash, cash equivalents and short-term investments will be sufficient to fund our projected operations into late 2027.”
SEC MD&A · August 11, 2026
Accumulated deficit as of June 30, 2026
“as of June 30, 2026, we had an accumulated deficit of $151.9 million.”
SEC MD&A · August 11, 2026
Lead candidate ARD-101 and ARD-201 program
“lead product candidate, ARD-101, and our ARD-201 program, we are also developing other programs for the potential treatment of indications with high unmet need, including other indications that may be treated by activating TAS2R signaling.”
SEC MD&A · November 13, 2025
No ATM sales as of June 30, 2026
“As of June 30, 2026, we have not sold any shares of common stock under the ATM Facility.”
SEC MD&A · August 11, 2026
Risks & what to watch (4)›
Key risks
- No approved products or revenue — Company has no commercial products and has never generated revenue from product sales; future revenue depends on regulatory approval [sec_mda · as of 2026-08-11].
- Clinical and regulatory uncertainty — Success of ARD-101 and other candidates is uncertain; clinical trials may fail or be delayed, and regulatory approval is not guaranteed [sec_mda · as of 2026-08-11].
- Reliance on third parties — Company depends on third-party contract research organizations and manufacturers for clinical trials and drug supply [sec_mda · as of 2026-08-11].
- Limited operating history and losses — Since inception in 2017, company has incurred significant net losses and negative cash flows; expects losses to increase [sec_mda · as of 2026-08-11].
What to watch
- Initiation, progress, and results of clinical trials for ARD-101 and ARD-201 [sec_mda · as of 2026-08-11].
- Any updates on regulatory strategy and interactions with the FDA or other agencies [sec_mda · as of 2026-08-11].
- Cash burn rate and any future capital raises, including potential use of the ATM facility [sec_mda · as of 2026-08-11].
- Partnership or collaboration announcements that could provide development or commercialization expertise [sec_mda · as of 2026-08-11].
Sources: SEC MD&A · Generated August 24, 2026 · How we verify sources →
Run Aardvark Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Aardvark Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
12.9 months
D/E 0.09 · 0% dilution
Lead: Phase 3
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
79
Total value held
$26.3M
| Holder | Shares | Value |
|---|---|---|
| citadel advisors llc | 1,295,677 | $4.9M |
| vanguard capital management llc | 1,108,202 | $4.2M |
| laurion capital management lp | 1,034,459 | $3.9M |
| blackrock, inc. | 792,571 | $3.0M |
| tetragon partners gp ltd | 316,621 | $1.2M |
| geode capital management, llc | 309,449 | $1.2M |
| adage capital partners gp, l.l.c. | 300,000 | $1.1M |
| state street corp | 199,322 | $751K |
| two sigma investments, lp | 163,355 | $616K |
| ubs group ag | 157,888 | $595K |
Showing top 10 of 79 institutional holders of Aardvark Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 19, 2026- % of float
- 8.8%
- Days to cover
- 7.0
- Shares short
- 1,261,941
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AARD short interestGovernance
Frequently asked questions
What is the AI investment thesis for Aardvark Therapeutics, Inc.?
Aardvark Therapeutics is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies that activate TAS2R bitter taste receptors for metabolic and inflammatory diseases, with lead candidate ARD-101 in clinical development.
What is Aardvark Therapeutics, Inc.'s lead drug candidate?
Aardvark Therapeutics, Inc.'s most advanced tracked candidate is ARD-101 (Phase 3) for Hyperphagia.
Who is the CEO of Aardvark Therapeutics, Inc.?
Dr. Tien-Li Lee M.D. is the chief executive officer of Aardvark Therapeutics, Inc. (AARD).
Where is Aardvark Therapeutics, Inc. headquartered?
Aardvark Therapeutics, Inc. (AARD) is headquartered in San Diego, CA, United States.
What therapeutic areas does Aardvark Therapeutics, Inc. focus on?
Aardvark Therapeutics, Inc. develops therapies across Rare Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.